ROS1 rearrangement-targeting unecritinib is a potential new first-line strategy Presented ByDr Shun Lu, Shanghai Chest Hospital, China TrialPhase 2 ConferenceELCC 2022 25 May, 2022 12:40
Entrectinib treatment in patients with ROS1+ NSCLC TrialSTARTRK-2, STARTRK-1, ALKA-372-001 ConferenceWClC 2018 21 November, 2018 21:57